|
| Status |
Public on Apr 30, 2011 |
| Title |
BLM and SCGB3A2 vs BLM treated rep 4 |
| Sample type |
RNA |
| |
|
| Channel 1 |
| Source name |
administration of BLM followed by intravenous injection of PBS
|
| Organism |
Mus musculus |
| Characteristics |
strain: C57BL/6
tissue: lung
|
| Treatment protocol |
Eight unit/kg of bleomycin (BLM) (Sigma-Aldrich, St. Louis, MO) or PBS was directly administered once by intratracheal intubation into C57BL/6N mice using the BioLITE system (BioTex, Inc., Houston, TX). Recombinant mouse (rm) SCGB3A2 (1.5 mg/kg/day) was intravenously administered.
|
| Growth protocol |
C57BL/6N mice (NCI-Frederick) were maintained under a standard 12-hrs light/12-hrs dark cycle with water and chow provided ad libitum. At least ten 7-8-week-old C57BL/6N mice were prepared for each group.
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Total RNAs were purified using TRIzol (Invitrogen, Carlsbad, CA) and RNAeasy (QIAGEN, Valencia, CA) from lungs of mice treated with SCGB3A2/PBS 21 days after initial administraion of BLM/PBS or mice 12 hrs after SCGB3A2 treatment.
|
| Label |
Cy3
|
| Label protocol |
Total RNA were reverse-transcribed to label with Cy3 and Cy5 (GE Healthcare Life Sciences, Piscataway, NJ) using FairPlay Microarray Labeling Kit (Stratagene, La Jolla, CA) or SuperScriptTM Indirect cDNA Labeling Core Kit (Invitrogen), respectively.
|
| |
|
| Channel 2 |
| Source name |
administration of BLM followed by intravenous injection of SCGB3A2
|
| Organism |
Mus musculus |
| Characteristics |
strain: C57BL/6
tissue: lung
|
| Treatment protocol |
Eight unit/kg of bleomycin (BLM) (Sigma-Aldrich, St. Louis, MO) or PBS was directly administered once by intratracheal intubation into C57BL/6N mice using the BioLITE system (BioTex, Inc., Houston, TX). Recombinant mouse (rm) SCGB3A2 (1.5 mg/kg/day) was intravenously administered.
|
| Growth protocol |
C57BL/6N mice (NCI-Frederick) were maintained under a standard 12-hrs light/12-hrs dark cycle with water and chow provided ad libitum. At least ten 7-8-week-old C57BL/6N mice were prepared for each group.
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Total RNAs were purified using TRIzol (Invitrogen, Carlsbad, CA) and RNAeasy (QIAGEN, Valencia, CA) from lungs of mice treated with SCGB3A2/PBS 21 days after initial administraion of BLM/PBS or mice 12 hrs after SCGB3A2 treatment.
|
| Label |
Cy5
|
| Label protocol |
Total RNA were reverse-transcribed to label with Cy3 and Cy5 (GE Healthcare Life Sciences, Piscataway, NJ) using FairPlay Microarray Labeling Kit (Stratagene, La Jolla, CA) or SuperScriptTM Indirect cDNA Labeling Core Kit (Invitrogen), respectively.
|
| |
|
| |
| Hybridization protocol |
According to FairPlay Kit (Catalog #252002, Stratagene, La Jolla, CA) instructions.
|
| Scan protocol |
Scanned on a GenePix 4000A.According to GenePix protocol.
|
| Description |
Gene regulation by administration of BLM followed by intravenous injection of SCGB3A2 or PBS
|
| Data processing |
LOWESS normalized, background subtracted VALUE data obtained from log2 of processed Red signal/processed Green signal. Agilent software was used.
|
| |
|
| Submission date |
Apr 28, 2010 |
| Last update date |
Apr 30, 2011 |
| Contact name |
Reiko Kurotani |
| E-mail(s) |
[email protected]
|
| Phone |
+81-45-787-2575
|
| Fax |
+81-45-788-1470
|
| URL |
http://www.yokohama-cu.ac.jp/
|
| Organization name |
Yokohama City University School of Medicine
|
| Lab |
Cardiovascular　Research Institute
|
| Street address |
3-9,fukuura,kanazawa-ku
|
| City |
Yokohama |
| State/province |
Kanagawa |
| ZIP/Postal code |
236-0004 |
| Country |
Japan |
| |
|
| Platform ID |
GPL4200 |
| Series (1) |
| GSE21560 |
SCGB3A2 suppresses bleomycin-induced pulmonary fibrosis through activation of STAT1 and up-regulation of SMAD7　 |
|
